Open Access

Clinical outcomes of second‑line chemotherapy after gemcitabine and cisplatin plus S‑1 treatment for patients with advanced biliary tract cancer in the KHBO1401‑3A study

  • Authors:
    • Yoshitaro Shindo
    • Hiroaki Nagano
    • Masashi Kanai
    • Shogo Kobayashi
    • Hiroshi Wada
    • Daisuke Sakai
    • Hidetoshi Eguchi
    • Hideo Baba
    • Hirofumi Kamachi
    • Tadatoshi Takayama
    • Masaki Ueno
    • Masahiro Takahashi
    • Yuki Nakagami
    • Kenichi Yoshimura
    • Etsuro Hatano
    • Tatsuya Ioka
  • View Affiliations

  • Published online on: January 11, 2023     https://doi.org/10.3892/or.2023.8478
  • Article Number: 41
  • Copyright: © Shindo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Since the completion of the KHBO1401 study, which evaluated the efficacy of the combination of gemcitabine (GEM) and cisplatin (GC) compared with GC plus S‑1 (GCS), GCS has become a standard chemotherapy for patients with advanced biliary tract cancer (BTC). However, there are currently no data revealing second‑line therapy options after GCS. The present study aimed to evaluate the survival outcomes of patients receiving second‑line chemotherapy for advanced BTC, refractory or intolerant to GCS, using data from the KHBO1401 study. Patients who received a second‑line treatment after GCS chemotherapy between July 2014 and February 2016 were retrospectively studied. Overall survival (OS) was calculated from the day of GCS treatment failure or the first day of second‑line chemotherapy to the final follow‑up date or until death from any cause. Among 83 patients refractory or intolerant to GCS chemotherapy, 51 (61%) received second‑line chemotherapy, including GCS (n=8), GC (n=15), GEM (n=6), GEM plus S‑1 (GS) (n=4) and S‑1 (n=18). The 6‑ and 12‑month OS rates were 66.7 and 44.4%, respectively, following second‑line chemotherapy, and 6.3 and 3.1%, respectively, in the best supportive care group (P<0.0001). In addition, the 12‑ and 24‑month OS rates were 59.3 and 36.2%, respectively, in the multidrug chemotherapy group, and 26.9 and 9.0%, respectively, in the single‑agent chemotherapy group (P=0.0191). These results suggested that second‑line combination chemotherapy is a viable treatment option for patients with advanced BTC that is refractory or intolerant to first‑line GCS therapy.
View Figures
View References

Related Articles

Journal Cover

February-2023
Volume 49 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shindo Y, Nagano H, Kanai M, Kobayashi S, Wada H, Sakai D, Eguchi H, Baba H, Kamachi H, Takayama T, Takayama T, et al: Clinical outcomes of second‑line chemotherapy after gemcitabine and cisplatin plus S‑1 treatment for patients with advanced biliary tract cancer in the KHBO1401‑3A study. Oncol Rep 49: 41, 2023
APA
Shindo, Y., Nagano, H., Kanai, M., Kobayashi, S., Wada, H., Sakai, D. ... Ioka, T. (2023). Clinical outcomes of second‑line chemotherapy after gemcitabine and cisplatin plus S‑1 treatment for patients with advanced biliary tract cancer in the KHBO1401‑3A study. Oncology Reports, 49, 41. https://doi.org/10.3892/or.2023.8478
MLA
Shindo, Y., Nagano, H., Kanai, M., Kobayashi, S., Wada, H., Sakai, D., Eguchi, H., Baba, H., Kamachi, H., Takayama, T., Ueno, M., Takahashi, M., Nakagami, Y., Yoshimura, K., Hatano, E., Ioka, T."Clinical outcomes of second‑line chemotherapy after gemcitabine and cisplatin plus S‑1 treatment for patients with advanced biliary tract cancer in the KHBO1401‑3A study". Oncology Reports 49.2 (2023): 41.
Chicago
Shindo, Y., Nagano, H., Kanai, M., Kobayashi, S., Wada, H., Sakai, D., Eguchi, H., Baba, H., Kamachi, H., Takayama, T., Ueno, M., Takahashi, M., Nakagami, Y., Yoshimura, K., Hatano, E., Ioka, T."Clinical outcomes of second‑line chemotherapy after gemcitabine and cisplatin plus S‑1 treatment for patients with advanced biliary tract cancer in the KHBO1401‑3A study". Oncology Reports 49, no. 2 (2023): 41. https://doi.org/10.3892/or.2023.8478